| Literature DB >> 16445857 |
Simon Cauchemez1, Laura Temime, Alain-Jacques Valleron, Emmanuelle Varon, Guy Thomas, Didier Guillemot, Pierre-Yves Boëlle.
Abstract
BACKGROUND: Recent trends of pneumococcal colonization in the United States, following the introduction of conjugate vaccination, indicate that non-vaccine serotypes tend to replace vaccine serotypes. The eventual extent of this replacement is however unknown and depends on serotype-specific carriage and transmission characteristics.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16445857 PMCID: PMC1382230 DOI: 10.1186/1471-2334-6-14
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Results of serotyping during follow-up of 4,488 children in 81 schools, January-May 2000, France.
| Frequency (%) | ||
| Serotypes with at least 30 swabs | ||
| Vaccine serotypes† | 19F | 403 (4.1) |
| 6B | 313 (3.2) | |
| 23F | 274 (2.8) | |
| 14 | 191 (1.9) | |
| 18C | 79 (0.8) | |
| 9V | 79 (0.8) | |
| Non-vaccine serotypes | 6A | 281 (2.9) |
| 3 | 238 (2.4) | |
| 19A | 212 (2.2) | |
| 11A | 80 (0.8) | |
| 15A | 72 (0.7) | |
| 15B | 54 (0.5) | |
| 23A | 46 (0.5) | |
| 17F | 44 (0.4) | |
| 10A | 42 (0.4) | |
| 9L | 32 (0.3) | |
| Other serotypes | 247 (2.5) | |
| Non-colonized | 7,170 (72.7) | |
| Total | 9,857 (100.0) |
† Serotype included in the 7-valent conjugate vaccine.
Figure 1Swabs collected in a school participating in the study. "0" indicates that the sample was taken but no serotype was detected; otherwise, serotype number is given.
Figure 2Data augmentation strategy to estimate transmission parameters of . The observed data consist of the times when swabs are collected in the school. The data are augmented with the times of colonization/decolonization. In the MCMC algorithm, augmented periods of carriage may be added/suppressed, split/combined; and the times of colonization/decolonization may change.
Posterior mean and 95% credible interval of transmission parameters of S. pneumoniae according to serotype inclusion in the vaccine. Transmission parameters consist of the mean duration of carriage μ, the child to child transmission rate β and the Secondary Attack Rate (SAR).
| Vaccine serotype* | Non-vaccine serotype† | Ratio | ||||
| Mean | 95% CI‡ | Mean | 95% CI‡ | Mean | 95% CI‡ | |
| 23 | 21, 25 | 22 | 20, 24 | 1.06 | 0.94, 1.18 | |
| 4.6 | 4.2, 5.0 | 5.1 | 4.5, 5.6 | 0.91 | 0.80, 1.05 | |
| 3.4 | 3.2, 3.7 | 3.6 | 3.3, 3.8 | 0.97 | 0.88, 1.06 | |
| 2.1 | 1.9, 2.2 | 2.2 | 2.0, 2.3 | 0.97 | 0.88, 1.06 | |
| 1.1 | 1.0, 1.2 | 1.1 | 1.0, 1.2 | 0.97 | 0.88, 1.06 | |
* Serotypes 6B, 9V, 14, 18C, 19F, 23F which are included in the 7-valent conjugate vaccine were selected for analysis (at least 30 positive swabs). Vaccine serotype 4 was not selected for analysis because it was isolated in 10 swabs only.
† Serotypes 6A, 3, 19A, 11A, 15A, 15B, 23A, 17F, 10A, 9L were selected for analysis.
‡ CI, credible interval.
§n, size of the school.
Figure 3Posterior predictive check. Panel a and b: Predictive distribution of the number of consecutive swabs in which the same serotype was detected for non-vaccine (panel a) and vaccine (panel b) serotypes. Panel c: predictive distribution of the serotype-specific average prevalence given detection of the serotype in the school. Boxplots give quantiles 2.5%, 25%, 50%, 75% and 97.5% of the distributions; circles indicate observed values. The predictive distributions are derived from 700 epidemics simulated with transmission parameters drawn from the posterior distribution.